Por: The Advocate Health November 16, 2022
What is the Lumipulse test for Alzheimer’s disease?In May, the U.S. Food and Drug Administration permitted marketing of the Lumipulse (G B-Amyloid Ratio [1-42/1-40]) test to Fujirebio Diagnostics, Inc. of Malvern, Pennsylvania. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA-authorized in vitro diagnostic test in the United States to aid in the assessment of B-Amyloid pathology in patients being... + full article
The Advocate USA Health November 16, 2022
Are U.S. veterans more at risk for Alzheimer’s or other dementias?The U.S. is in the midst of a dramatic rise in the number of veterans with Alzheimer’s disease and other dementias, and many of these new cases are directly attributable to military service.According to a 2017... + más
Stroke can lead to vascular dementia: Alzheimer's Q&A | The Advocate
How do you assess the risk of Alzheimer’s disease?Alzheimer’s disease is the only disease in the top 10 causes of death in the United States that cannot be prevented, slowed, or cured. It is not fully understood what causes the disease, but probable causes could be linked to... + más
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
Slate USA Tech October 30, 2022
For decades, there had been no real medical game changers in Alzheimer’s research—until last year. The FDA approved a controversial drug, one with only mixed clinical results. At this point, even the manufacturer of this drug, called Aduhelm, has all but abandoned it. There... + más
How To Spot The Early Signs Of Alzheimer's | Newsweek
Forbes USA Tech October 22, 2022
A person walks on a suspended rope bridge in the clouds. Extreme attraction.getty This article is the fourth installment in my series on Alzheimer’s disease. Read more about Alzheimer’s disease in , , and of the series. The pharmaceutical and biotech companies, Eisai and... + más
Variety of factors play a role in the development of Alzheimer's | The Advocate
Newsweek USA Health September 24, 2022
The Alzheimer's Association defines Alzheimer's as a brain disease that causes a slow decline in memory, thinking and reasoning skills. Dementia refers to the symptoms of Alzheimer's that can worsen over time.They predict that by 2050, the number of people aged 65... + más
There's a growing dementia crisis in the veteran community: Alzheimer's Q&A | The Advocate
Portland Press Herald USA Health September 24, 2022
A study using the electronic health records of more than 6 million Americans over age 65 found that those who had COVID-19 ran a greater risk of receiving a new diagnosis of Alzheimer’s disease within a year. The study, led by researchers at Case Western Reserve University... + más
The Advocate USA Health September 17, 2022
What is the Lumipulse test for Alzheimer’s disease?In May, the U.S. Food and Drug Administration permitted marketing of the Lumipulse (G B-Amyloid Ratio [1-42/1-40]) test to Fujirebio Diagnostics, Inc. of Malvern, Pennsylvania. The test, which was granted Breakthrough Device... + más
Alzheimer's Q&A: Sildenafil has potential as Alzheimer's drug | The Advocate
About iurex | Privacy Policy | Disclaimer |